Beyond surgical technique: modifiable risk factors and evolving treatment paradigms in bladder cancer surgery

Contextualizing the Development of Anti-HER2 Therapies for Patients with Advanced Urothelial Carcinoma

Take Home Message Antibody-drug conjugates (ADCs) have revolutionized the treatment landscape for metastatic urothelial carcinoma. Encouraging clinical activity of HER2-directed ADCs, including disitamab vedotin, has been observed in early-phase trials. Recent promising results from the RC48-C016 trial raise important questions. We discuss issues that include optimal frontline treatment selection, subsequent-line treatment sequencing, and the generalizability of the findings.

Homologous recombination deficiency and genomic alterations in advanced prostate cancer: insights for precision therapy

Abstract Background the homologous recombination deficiency signature (HRDsig) is emerging as a novel potential predictor of PARP-inhibitor (PARPi) response. We compared genomic alterations (GA) across BRCA2-loss, BRCA2 short variant–mutated (svmut), and BRCA2–wild type (wt) clinically advanced prostate carcinoma (CAPC) samples, combined with an assessment of HRDsig status to gain a better understanding of these biomarkers. Methods Comprehensive genomic profiling (CGP) was performed on 22&nbs...

Anomalous Coronary Artery Origin from Pulmonary Artery and Coronary Fistulas: A Review About Coronary Steal Phenomenon

Anomalous coronary artery origin from pulmonary artery and coronary–pulmonary fistulas are the major causes of ischemic cardiopathy in children. Both anomalies are characterized by a connection between a higher and a lower pressure chamber causing coronary steal. However, several mechanisms and associated lesions may be responsible of the different presentations of the “coronary steal phenomenon”. The aim of this review is to highlight the different embryology, anatomical features, clinical p...